
Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …
Pharmafocus presents a round-up of developments in manufacturing, including facility updates from GW and Viva Biopharm, GMP problems at an …
Sativex, the cannabis-derived product developed by GW Pharmaceuticals, could be finally set for European approval after five years of delay. …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

